NovaBay Pharmaceuticals Future Growth
Future criteria checks 1/6
NovaBay Pharmaceuticals is forecast to grow earnings and revenue by 90.2% and 7.5% per annum respectively while EPS is expected to grow by 150.4% per annum.
Key information
90.2%
Earnings growth rate
150.4%
EPS growth rate
| Pharmaceuticals earnings growth | 21.4% |
| Revenue growth rate | 7.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 14 Aug 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 16 | -3 | N/A | 0 | 1 |
| 12/31/2025 | 15 | -2 | N/A | -1 | 2 |
| 12/31/2024 | 12 | -5 | N/A | -3 | 1 |
| 6/30/2024 | 14 | -17 | -3 | -3 | N/A |
| 3/31/2024 | 15 | -19 | -4 | -4 | N/A |
| 12/31/2023 | 15 | -17 | -4 | -4 | N/A |
| 9/30/2023 | 13 | -15 | -5 | -5 | N/A |
| 6/30/2023 | 13 | -19 | -6 | -6 | N/A |
| 3/31/2023 | 13 | -17 | -6 | -6 | N/A |
| 12/31/2022 | 14 | -16 | -7 | -7 | N/A |
| 9/30/2022 | 14 | -9 | -10 | -10 | N/A |
| 6/30/2022 | 13 | -5 | -10 | -10 | N/A |
| 3/31/2022 | 12 | -5 | -10 | -10 | N/A |
| 12/31/2021 | 10 | -7 | -9 | -9 | N/A |
| 9/30/2021 | 9 | -7 | -6 | -6 | N/A |
| 6/30/2021 | 8 | -8 | -6 | -6 | N/A |
| 3/31/2021 | 10 | -11 | -5 | -5 | N/A |
| 12/31/2020 | 10 | -11 | -5 | -5 | N/A |
| 9/30/2020 | 10 | -13 | -5 | -5 | N/A |
| 6/30/2020 | 9 | -10 | -5 | -5 | N/A |
| 3/31/2020 | 7 | -8 | -6 | -6 | N/A |
| 12/31/2019 | 7 | -10 | -8 | -8 | N/A |
| 9/30/2019 | 8 | -8 | -9 | -8 | N/A |
| 6/30/2019 | 10 | -10 | -9 | -9 | N/A |
| 3/31/2019 | 11 | -9 | -8 | -8 | N/A |
| 12/31/2018 | 13 | -7 | -6 | -6 | N/A |
| 9/30/2018 | 15 | -4 | -7 | -7 | N/A |
| 6/30/2018 | 16 | -5 | -5 | -5 | N/A |
| 3/31/2018 | 17 | -6 | N/A | -5 | N/A |
| 12/31/2017 | 18 | -7 | N/A | -6 | N/A |
| 9/30/2017 | 16 | -10 | N/A | -4 | N/A |
| 6/30/2017 | 15 | -11 | N/A | -8 | N/A |
| 3/31/2017 | 14 | -12 | N/A | -9 | N/A |
| 12/31/2016 | 12 | -13 | N/A | -12 | N/A |
| 9/30/2016 | 9 | -16 | N/A | -16 | N/A |
| 6/30/2016 | 7 | -17 | N/A | -16 | N/A |
| 3/31/2016 | 6 | -19 | N/A | -19 | N/A |
| 12/31/2015 | 4 | -19 | N/A | -19 | N/A |
| 9/30/2015 | 3 | -19 | N/A | -18 | N/A |
| 6/30/2015 | 2 | -18 | N/A | -17 | N/A |
| 3/31/2015 | 1 | -16 | N/A | -15 | N/A |
| 12/31/2014 | 1 | -15 | N/A | -15 | N/A |
| 9/30/2014 | 1 | -15 | N/A | -16 | N/A |
| 6/30/2014 | 2 | -14 | N/A | -15 | N/A |
| 3/31/2014 | 3 | -16 | N/A | -14 | N/A |
| 12/31/2013 | 3 | -16 | N/A | -13 | N/A |
| 9/30/2013 | 4 | -14 | N/A | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: B9P0 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: B9P0 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: B9P0 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: B9P0's revenue (7.5% per year) is forecast to grow faster than the German market (5.1% per year).
High Growth Revenue: B9P0's revenue (7.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if B9P0's Return on Equity is forecast to be high in 3 years time